Literature DB >> 1967538

Effects of tiazofurin on guanine nucleotide binding regulatory proteins in HL-60 cells.

S M Kharbanda1, M L Sherman, D W Kufe.   

Abstract

Guanine nucleotide binding proteins (G proteins) are regulatory molecules that couple membrane receptors to effector systems such as adenylate cyclase and phospholipase C. The alpha subunits of G proteins bind to guanosine 5'-diphosphate (GDP) in the unstimulated state and guanosine 5' triphosphate (GTP) in the active state. Tiazofurin (2-beta-D-ribofuranosylthiazole-4-carboxamide), a specific inhibitor of inosine monophosphate (IMP) dehydrogenase, decreases guanylate synthesis from IMP in HL-60 promyelocytic leukemia cells and depletes intracellular guanine nucleotide pools. This study demonstrates that treatment of HL-60 cells with tiazofurin is associated with a fourfold increase in membrane binding sites for the nonhydrolyzable analogue GDP beta S. This increase in binding sites was associated with a 3.2-fold decrease in GDP beta S binding affinity. Similar findings were obtained with GTP gamma S. These effects of tiazofurin treatment on guanine nucleotide binding were also associated with decreased adenosine diphosphate-ribosylation of specific G protein substrates by cholera and pertussis toxin. The results further demonstrate that tiazofurin treatment results in inhibition of G protein-mediated transmembrane signaling mechanisms. In this regard, stimulation of adenylate cyclase by prostaglandin E2 was inhibited by over 50% in tiazofurin-treated cells. Furthermore, tiazofurin treatment resulted in inhibition of N-formylmethionylleucylphenylalanine-induced stimulation of phospholipase C. Taken together, these results indicate that tiazofurin acts at least in part by inhibiting the ability of G proteins to function as transducers of intracellular signals.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1967538

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  4 in total

1.  Crystal structure of human type II inosine monophosphate dehydrogenase: implications for ligand binding and drug design.

Authors:  T D Colby; K Vanderveen; M D Strickler; G D Markham; B M Goldstein
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-30       Impact factor: 11.205

2.  Cloning and functional characterization of GMPR2, a novel human guanosine monophosphate reductase, which promotes the monocytic differentiation of HL-60 leukemia cells.

Authors:  Jia Zhang; Weiping Zhang; Dajin Zou; Guoyou Chen; Tao Wan; Minghui Zhang; Xuetao Cao
Journal:  J Cancer Res Clin Oncol       Date:  2003-03-01       Impact factor: 4.553

3.  Inosine-5'-monophosphate dehydrogenase is a rate-determining factor for p53-dependent growth regulation.

Authors:  Y Liu; S A Bohn; J L Sherley
Journal:  Mol Biol Cell       Date:  1998-01       Impact factor: 4.138

4.  Newer human inosine 5'-monophosphate dehydrogenase 2 (hIMPDH2) inhibitors as potential anticancer agents.

Authors:  Chetan P Shah; Prashant S Kharkar
Journal:  J Enzyme Inhib Med Chem       Date:  2018-12       Impact factor: 5.051

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.